CN1961904A - Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof - Google Patents
Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof Download PDFInfo
- Publication number
- CN1961904A CN1961904A CN 200510115952 CN200510115952A CN1961904A CN 1961904 A CN1961904 A CN 1961904A CN 200510115952 CN200510115952 CN 200510115952 CN 200510115952 A CN200510115952 A CN 200510115952A CN 1961904 A CN1961904 A CN 1961904A
- Authority
- CN
- China
- Prior art keywords
- radix ginseng
- extract
- total saponins
- pharmaceutical composition
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, its preparing process and use thereof, wherein the composition mainly comprises ginseng saponins and carthamus tinctorius yellow color. Various injection preparations and pharmacologically allowable dose forms such as oral administration preparations can be produced through charging auxiliary materials. The preparation of the composition is mainly used for treating ischemic cerebral apoplexy, angina pectoris caused by coronary disease, cardiac functional insufficiency, apoplexy after-effect, hepatorenal syndrome, coronary heart disease, diabetes and complications. The preparation has the advantages of definite constituents, fine external appearance, controllable quality, and appreciable curative effect.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition for the treatment of cardiovascular and cerebrovascular disease and its production and application, belong to technical field of medicaments.
Technical background
According to national health department's investigation statistics, 2004, ten thousand people died from cardiovascular and cerebrovascular disease surplus China had 260, and people's death was just arranged in average per 12 seconds, cardiovascular and cerebrovascular disease patient sum nearly 1.5 hundred million, and annual control expenditure surpasses 100,000,000,000.And the cardiovascular and cerebrovascular disease patient generally has hyperlipemia, hypertension, high blood viscosity, thrombosis, sclerosis of blood vessels, angiostenosis etc.If the Therapeutic Method of " medicine one is controlled, treated the head when the head aches, foot cure foot bitterly " according at present, so the patient must eat every day surplus " lipid lowerers, the depressor, fall the sticking medicine of blood, Pimobendane, thrombolytic medicine " etc. five, six kind even ten in the kind, Western medicine.Better prevent and treat purpose in order to reach, a large amount of research has been done by many inventors and medicine enterprise, and some outstanding treatment products also are provided; As: number of patent application is: 200410071542.4, name is called the patent application of " Chinese medicine preparation of the treatment heart, cerebrovascular disease and preparation method thereof ", and the disease that it is used for the treatment for the treatment of cardiac and cerebral vascular diseases has definite curative effect; But in further investigation, find, adopt the effective site compatibility can not only reduce patient's dose, remove the strong composition of some toxic and side effects in the medicinal substances extract, the safety of preparation and the controllability of quality have been improved, greatly improve curative effect, and more help the molding of preparation, reduced some unnecessary technologies in the forming process.
Summary of the invention
The objective of the invention is to: a kind of pharmaceutical composition for the treatment of cardiovascular and cerebrovascular disease and its production and application is provided; The present invention is directed to prior art, according to cardiovascular and cerebrovascular disease such as coronary heart disease, cerebral thrombosis, alzheimer disease etc. all contract because of blood vessel is narrow, reason such as blood flow minimizing causes the diseases induced principle of blood supply insufficiency, on the basis of experiment screening, adopt Radix Ginseng total saponins, Carthamus yellow compatibility to make preparation, optimize best prescription and technology; The product that obtains, particularly ejection preparation product can play activating blood circulation to dissipate blood stasis, TONGMAI SHULUO, improve blood circulation and metabolism.For example coronary heart disease is that coronary atherosclerosis causes myocardial ischemia, anoxia and the heart disease that causes, and two medicines share, and can play to improve the myocardial metabolism effect, increase coronary flow, and the blood that improves cardiac muscle is provided with the effect of allevating angina pectoris.The present invention has curative effect preferably for treating cardiovascular and cerebrovascular disease such as coronary heart disease, angina pectoris, arrhythmia, cerebral thrombosis, alzheimer disease etc.But and the little patients life-time service of untoward reaction of the present invention.
The present invention constitutes like this: calculate according to percentage by weight, it is to be made by Radix Ginseng total saponins 1～99% and Flos Carthami flavochrome 99～1% and suitable adjuvant.Be preferably: calculate according to percentage by weight, it is to be made by Radix Ginseng total saponins 95～50% and Flos Carthami flavochrome 5～50% and suitable adjuvant.Say accurately: calculate according to percentage by weight, it is to be made by Radix Ginseng total saponins 90～50%, Carthamus yellow 10～50% and suitable adjuvant.Radix Ginseng total saponins in the described prescription can be the highly finished product of panaxynol extract, Radix Ginseng water extract, Radix Ginseng water extract-alcohol precipitation extract, Radix Ginseng semi-bionic extraction thing, Radix Ginseng supercritical extract or above each extract; Carthamus yellow can be the highly finished product of Flos Carthami alcohol extract, Flos Carthami water extract, Flos Carthami water extract-alcohol precipitation extract, Flos Carthami semi-bionic extraction thing, Flos Carthami supercritical extract or above each extract.Described preparation be directly used in the injection of drug administration by injection, directly for the venous transfusion of intravenous drip, need be used for the concentrated solution for injection of intravenous drip and injectable sterile powder and aseptic block and tablet, capsule, granule, drop pill, pellet, pill, soft capsule, oral liquid, oral cavity disintegration tablet or the dispersible tablet that makes with freeze-drying or spray drying method after the dilution.Described preparation can make on the basis that Radix Ginseng total saponins, Carthamus yellow is prepared into liposome or pro-liposome.Contain saponin component and Flos Carthami flavochrome in the preparation, calculate by weight percentage, in the preparation saponin component, carthamus tinctorius yellow color content sum be not less than deduction adjuvant amount and water quantities in the preparation total solid 50%.Calculate according to percentage by weight, the content of saponin component is not less than 50% in the Radix Ginseng total saponins.
The pharmaceutical composition of described treatment cardiovascular and cerebrovascular disease:
A, described Carthamus yellow are preparations like this: get flos carthami, adding entry or alcoholic solution after the pulverizing extracts, merge extractive liquid,, filter, concentrate the Flos Carthami crude extract, adopt in ethanol precipitation, column chromatography, extraction, the flocculent precipitation one or more to unite on this basis to use carry out suitably refining, Carthamus yellow;
B, described Radix Ginseng total saponins effective site are preparations like this: get the ginseng crude drug, adding entry or alcoholic solution after the pulverizing extracts, merge extractive liquid,, filter, concentrate the Radix Ginseng crude extract, adopt in ethanol precipitation, column chromatography, extraction, the flocculent precipitation one or more to unite on this basis to use carry out suitably refining, Radix Ginseng total saponins effective site.
The Injectable sterile block of described compositions prepares like this: get Radix Ginseng total saponins, Carthamus yellow, press medicine and added mannitol than 1: 2 with supplementary product consumption, add 1800ml water for injection, stirring makes dissolving, adjust pH to 5.5～6.5, add the injection water to 2000ml, mixing, the needle-use activated carbon of adding 0.5%, boiled 30 minutes, coarse filtration, reuse 0.45 μ m and 0.22 μ m microporous filter membrane filter, the filtrate packing, every bottle of 2.0ml, lyophilization, the equilibration time when the balance solidification point of phase I is 0 ℃ is 2 hours, i.e. the time of shelf temperature and product temperature basically identical; The second stage solidification point is from 0 ℃ during to minimum eutectic temperature-18 ℃, and shelf temperature and product temperature equilibration time are 2 hours; Phase III continues to be cooled to-45 ℃, needs 2.5 hours approximately, keeps this temperature 2.5 hours, freeze the jail fully until product, promptly begin evacuation, enter drying program, evacuation under-45 ℃ of constant temperature slowly heats up 2～4 ℃/h, to the lowest total of the melting point temperature, the time is about 12 hours, after sublimation drying is finished, continuation is under the low pressure condition, and it is dry to remove residual moisture to heat up, and the time is about 8～10 hours, kept more than 35 ℃ dry 2 hours, gland, promptly.
The pro-liposome of described compositions prepares like this: get Radix Ginseng total saponins, Carthamus yellow, add the phosphate buffer dissolving, add in the fused solution of fabaceous lecithin, cholesterol and 18-amine. mixing, stir supersound process, freezing, the dry powder that obtains sieves, promptly.
Described compositions is mainly used in diseases such as preparation treatment ischemia apoplexy, angina pectoris, cardiac insufficiency, apoplexy sequela, hepatorenal syndrome, heart and lung diseases, diabetes and complication thereof.
Compared with prior art, the applicant carried out lot of experiments, and filtering out the prescription for the treatment of diseases such as angina pectoris is Radix Ginseng total saponins, Carthamus yellow, and best compatibility scope is Radix Ginseng total saponins 90～50%, Carthamus yellow 10%～50%.Adopt good, the steady quality of prepared product appearance of the present invention.
For proving that medicine provided by the invention has effective effect, the applicant has carried out a series of experiments.
Experimental example 1: to the comparative study of different proportioning pharmacodynamics
We by antiplatelet aggregation test, suppress the mouse tail thrombotest, the prescription of different proportion has been carried out the screening test of system, the result is as follows.
The prescription research conclusion
| Formula number | Prescription is formed and ratio | The screening and assessment index | |
| Carthamus yellow: Radix Ginseng total saponins | Platelet suppression ratio (%) | Thrombosis suppression ratio (%) | |
| 1 2 3 4 5 6 7 | 1: 99 5: 95 10: 90 50: 50 99: 1 positive controls of model group | 0.36％ 49.5％ 52.4％ 63.7％ 62.9％ 49.2％ 63.1％ | -0.19％ 24.5％ 35.7％ 45.6％ 46.2％ 28.1％ 45.2％ |
By experimental result as can be known, Radix Ginseng total saponins, the best compatibility scope of Carthamus yellow are Radix Ginseng total saponins 90～50% and Carthamus yellow 10～50%.
Experimental example 2: injection Study on Forming
2.1 the selection of filler kind and consumption
2.1.1 the screening of filler kind
The applicant finds that in development suitable filler, filler loading are powder injection formulation molding and stable key factor, and in order to improve the quality of this powder injection formulation, at first, the applicant investigates the kind of filler, the results are shown in following table.
The screening of filler kind
| Filler | Mannitol | Glucose | Lactose | Gelatin hydrolysate | Glycine sodium |
| Medicine: filler mouldability | 1: 2 good | Not molding in 1: 2 | Not molding in 1: 2 | Not molding in 1: 2 | Not molding in 1: 2 |
As seen, because the eutectic point height of mannitol, good water solubility be beneficial to the lyophilizing and the molding of this product, and other filler all is not suitable for this product, so selection mannitol is filler.
2.1.2 the screening of mannitol consumption
Then, the applicant investigates the weight ratio of mannitol and effective ingredient, the results are shown in following table.
The mannitol consumption is to the influence of lyophilizing effect
| Medicine: mannitol | Color | Mouldability | Water solublity | Clarity |
| 1∶1.0 1∶1.5 1∶2.0 1∶2.5 | Yellow faint yellow yellowish white | Difference is good carefully | Difference is good carefully | Difference difference good job |
As seen, medicine: mannitol=1: 2.0 o'clock, formed product is effective, considers from economic angle, determines medicine: mannitol=1: 2.0.
Experimental example 3: preparation pharmacodynamic experiment
Protective effect to Acute Myocardial Ischemia in Rats: get the SD rat; body constitution amount 230～250g; male and female half and half; be divided into model group (giving the equivalent normal saline every day), oral liquid group of the present invention (administration every day 60mg/kg), injection group of the present invention (administration every day 60mg/kg), liposome group of the present invention (administration every day 60mg/kg) and Radix Ginseng/Flos Carthami 50/50 medical material proportioning injection group at random and (be called for short medical material compatibility group; administration every day 60mg/kg); every group 10; continuous 7 days, 1h ligation rat coronary artery left anterior descending branch after the last administration.Ventricle is got blood 3ml behind coronary ligation 3h, and centrifugal 5min prepares serum with the speed of 3000 * g, gets serum, measures corresponding index in the serum respectively with superoxide dismutase (SOD), malonaldehyde (MDA) test kit.Win rat heart and discharge hematocele in the chambers of the heart, inhale the branch that anhydrates, reject non-cardiac muscular tissues such as fatty blood vessel, wipe out atrium and right ventricle, stay left ventricle and weigh, calculate infarcted region (weight in wet base) and account for left ventricle (weight in wet base) percentage ratio with normal saline flushing and with filter paper.The results are shown in following table.
Influence to SOD, MDA in myocardial infarct size and the serum behind the rat coronary ligation
| Group | Heart infarction scope (%) | SOD(NU/ml) | MDA(nmol/ml) |
| Model group injection group of the present invention oral liquid group of the present invention liposome group of the present invention medical material compatibility group | 17.8±1.5 12.6±2.3 13.2±1.7 11.3±1.2 13.7±2.1 | 187.5±25.3 345.8±26.8 315.9±24.9 356.7±32.5 301.6±36.7 | 7.85±1.34 4.36±1.26 4.68±2.03 3.86±0.91 5.07±0.72 |
By experimental result as can be known, pharmaceutical preparation of the present invention can obviously improve SOD activity in the coronary ligation rat blood serum, has significantly suppressed the generation of MDA, and obviously reduces myocardial infarction district area, and the effect of lipidosome injection group is stronger.
Concrete embodiment
Embodiments of the invention 1: Radix Ginseng total saponins 50g Carthamus yellow 50g
Get Radix Ginseng total saponins, Carthamus yellow, press medicine and added mannitol than 1: 2 with supplementary product consumption, add 1800ml water for injection, stirring makes dissolving, adjust pH to 5.5～6.5, add the injection water to 2000ml, mixing, the needle-use activated carbon of adding 0.5%, boiled 30 minutes, coarse filtration, reuse 0.45 μ m and 0.22 μ m microporous filter membrane filter, the filtrate packing, every bottle of 2.0ml, lyophilization, the equilibration time when the balance solidification point of phase I is 0 ℃ is 2 hours, i.e. the time of shelf temperature and product temperature basically identical; The second stage solidification point is from 0 ℃ during to minimum eutectic temperature-18 ℃, and shelf temperature and product temperature equilibration time are 2 hours; Phase III continues to be cooled to-45 ℃, needs 2.5 hours approximately, keeps this temperature 2.5 hours, freeze the jail fully until product, promptly begin evacuation, enter drying program, evacuation under-45 ℃ of constant temperature, slowly heat up, 2～4 ℃/h, to the lowest total of the melting point temperature, the time is about 12 hours, after sublimation drying is finished, continuation is under the low pressure condition, and it is dry to remove residual moisture to heat up, and the time is about 8～10 hours, kept more than 35 ℃ dry 2 hours, gland promptly gets the Injectable sterile block, one time 2,1 time on the one, with using behind the 250ml0.9% physiological saline solution.Calculate by weight percentage, in the injection saponin component, carthamus tinctorius yellow color content sum be deduction adjuvant amount and water quantities in the preparation total solid 83%.
Embodiments of the invention 2: Radix Ginseng total saponins 50g Carthamus yellow 50g
Get Radix Ginseng total saponins, Carthamus yellow, add an amount of water for injection dissolving, by volume add 0.5% active carbon, boil, keep little 30min that boils, cold slightly filtration, filtrate adds the injection water to ormal weight, and boil adjust pH to 5.5～6.5,4 ℃ of cold preservations are spent the night, coarse filtration, fine straining add the injection water, divide to install to pacify and cut open bottle, seal sterilization, promptly get injection with small volume or concentrated solution for injection.
Embodiments of the invention 3: Radix Ginseng total saponins 90g Carthamus yellow 10g
Get Radix Ginseng total saponins, Carthamus yellow, add an amount of water for injection dissolving, by volume add 0.5% active carbon, boil, keep little 30min that boils, cold slightly filtration, filtrate adds the injection water to ormal weight, and boil adjust pH to 5.5～6.5,4 ℃ of cold preservations are spent the night, coarse filtration, fine straining add the injection water, divide to install to pacify and cut open bottle, seal sterilization, promptly get injection with small volume or concentrated solution for injection.
Embodiments of the invention 4: Radix Ginseng total saponins 90g Carthamus yellow 10g
Get Radix Ginseng total saponins, Carthamus yellow, press medicine and added mannitol than 1: 2 with supplementary product consumption, add 1800ml water for injection, stirring makes dissolving, adjust pH to 5.5～6.5, add the injection water to 2000ml, mixing, the needle-use activated carbon of adding 0.5%, boiled 30 minutes, coarse filtration, reuse 0.45 μ m and 0.22 μ m microporous filter membrane filter, the filtrate packing, every bottle of 2.0ml, lyophilization, the equilibration time when the balance solidification point of phase I is 0 ℃ is 2 hours, i.e. the time of shelf temperature and product temperature basically identical; The second stage solidification point is from 0 ℃ during to minimum eutectic temperature-18 ℃, and shelf temperature and product temperature equilibration time are 2 hours; Phase III continues to be cooled to-45 ℃, need 2.5 hours approximately, kept this temperature 2.5 hours, freeze the jail fully until product, promptly begin evacuation, enter drying program, evacuation under-45 ℃ of constant temperature, slowly heat up, 2～4 ℃/h, to the lowest total of the melting point temperature, time is about 12 hours, after sublimation drying is finished, continue under the low pressure condition, it is dry to remove residual moisture to heat up, time is about 8～10 hours, kept more than 35 ℃ dry 2 hours, and under aseptic condition, divided to install in the cillin bottle, promptly get injectable sterile powder.
Embodiments of the invention 5: Radix Ginseng total saponins 70g Carthamus yellow 30g
Get Radix Ginseng total saponins, Carthamus yellow, add an amount of water for injection dissolving, by volume add 0.5% active carbon, boil, keep little 30min that boils, cold slightly filtration, filtrate adds the injection water to ormal weight, and boil adjust pH to 5.5～6.5,4 ℃ of cold preservations are spent the night, coarse filtration, fine straining add the injection water, divide to install to pacify and cut open bottle, seal sterilization, promptly get injection with small volume or concentrated solution for injection.
Embodiments of the invention 6: Radix Ginseng total saponins 70g Carthamus yellow 30g
Get Radix Ginseng total saponins, Carthamus yellow, press medicine and added mannitol than 1: 2 with supplementary product consumption, add 1800ml water for injection, stirring makes dissolving, adjust pH to 5.5～6.5, add the injection water to 2000ml, mixing, the needle-use activated carbon of adding 0.5%, boiled 30 minutes, coarse filtration, reuse 0.45 μ m and 0.22 μ m microporous filter membrane filter, the filtrate packing, every bottle of 2.0ml, lyophilization, the equilibration time when the balance solidification point of phase I is 0 ℃ is 2 hours, i.e. the time of shelf temperature and product temperature basically identical; The second stage solidification point is from 0 ℃ during to minimum eutectic temperature-18 ℃, and shelf temperature and product temperature equilibration time are 2 hours; Phase III continues to be cooled to-45 ℃, need 2.5 hours approximately, kept this temperature 2.5 hours, freeze the jail fully until product, promptly begin evacuation, enter drying program, evacuation under-45 ℃ of constant temperature, slowly heat up, 2～4 ℃/h, to the lowest total of the melting point temperature, time is about 12 hours, after sublimation drying is finished, continue under the low pressure condition, it is dry to remove residual moisture to heat up, time is about 8～10 hours, kept more than 35 ℃ dry 2 hours, and under aseptic condition, divided to install in the cillin bottle, promptly get injectable sterile powder.
Embodiments of the invention 7: Radix Ginseng total saponins 95g Carthamus yellow 5g
Get Radix Ginseng total saponins, Carthamus yellow, mixing adds an amount of water for injection dissolving, by volume add 0.5% active carbon, boil, keep little 30min that boils, cold slightly filtration, filtrate add the injection water to ormal weight, adjust pH to 5.5～6.5, boil, 4 ℃ of cold preservations are spent the night, and coarse filtration, fine straining are 130 ℃ in inlet temperature, leaving air temp is 60 ℃, and air velocity is 20ms
-1Condition under spray drying get powder, packing promptly gets injectable sterile powder.
Embodiments of the invention 8: Radix Ginseng total saponins 80g Carthamus yellow 20g
Get Radix Ginseng total saponins, Carthamus yellow, add an amount of water for injection dissolving, add the glucose or the sodium chloride of ormal weight, by volume add 0.5% active carbon behind the mixed dissolution, boil, keep little 30min that boils, cold slightly filtration, filtrate add the injection water to ormal weight, again adjust pH to 5.5～6.5, boil, 4 ℃ of cold preservations are spent the night, and coarse filtration, fine straining add the injection water, packing, sterilization promptly gets glucose or sodium chloride intravenous infusion.
Embodiments of the invention 9: Radix Ginseng total saponins 60g Carthamus yellow 40g
With Radix Ginseng total saponins and Radix Salviae Miltiorrhizae total phenolic acids, Radix Notoginseng total arasaponins mix homogeneously, add 7% carboxymethyl starch sodium and 1.5% mannitol, compacting promptly gets oral cavity disintegration tablet in flakes.
Embodiments of the invention 10: Radix Ginseng total saponins 65g Carthamus yellow 35g
With Radix Ginseng total saponins and Radix Salviae Miltiorrhizae total phenolic acids, Radix Notoginseng total arasaponins mix homogeneously, to be that 1: 1.4 poloxamer is put in the rustless steel container with the principal agent ratio, add extract, mix homogeneously, be heated to 80-85 ℃, treat whole fusions after, 70-75 ℃ of insulation, mechanical high-speed stirs 15min to even, be transferred in the reservoir, the dropping liquid valve is regulated in 70～75 ℃ of insulations, splash in 30～35 ℃ the kerosene, drip apart from 5～6cm, drip 40～45 droplets/minute of speed, to the greatest extent and wipe kerosene the drop pill drop that forms, packing promptly gets drop pill.
Embodiments of the invention 11: Radix Ginseng total saponins 99g Carthamus yellow 1g
With Radix Ginseng total saponins and Carthamus yellow mix homogeneously, in principal agent: the ratio of adjuvant=1: 1.2 adds calcium sulfate, by principal agent: the ratio adding pregelatinized starch of adjuvant=1.1: 1, and press principal agent: the crospovidone of adjuvant=3: 1, evenly mixed, make soft material in right amount with 75% ethanol, cross 20 mesh sieve system granules, 50 ℃ of dryings are taken out, and cross 30 mesh sieve granulate, add an amount of Pulvis Talci, micropowder silica gel, evenly mixed, tabletting promptly gets dispersible tablet.
Embodiments of the invention 12: Radix Ginseng total saponins 1g Carthamus yellow 99g
With Radix Ginseng total saponins and Carthamus yellow mix homogeneously, add 2 times of amount starch, 0.5% lactose, 1.4% microcrystalline Cellulose with an amount of alcoholic solution system soft material, is granulated, and 75 ℃ of forced air dryings are granulated, and granulate promptly gets granule.
Embodiments of the invention 13: Radix Ginseng total saponins 75g Carthamus yellow 25g
With Radix Ginseng total saponins and Carthamus yellow mix homogeneously, add the starch of equivalent, mix homogeneously is granulated, and is encapsulated, promptly gets capsule.
Embodiments of the invention 14: Radix Ginseng total saponins 55g Carthamus yellow 45g
With Radix Ginseng total saponins and Carthamus yellow mix homogeneously, add distilled water, filter repeatedly, till the filtrate clarification., filter with absorbent cotton after the stirring and dissolving in filtrate with sucrose, it is an amount of to add distilled water on filter, shakes up, and promptly gets syrup.
Embodiments of the invention 15: Radix Ginseng total saponins 50g Carthamus yellow 50g
With Radix Ginseng total saponins, Carthamus yellow mix homogeneously, be dissolved in the phosphate buffer (0.1M) standby, a certain proportion of fabaceous lecithin, cholesterol are dissolved in the 18-amine. solution, add in the phosphate-buffered liquor of said medicine, the water-bath type Ultrasound Instrument is handled 10min, gets liposome turbid liquor, the phosphate buffer standardize solution, filtration sterilization, aseptic subpackaged, promptly get lipidosome injection.
Embodiments of the invention 16: Radix Ginseng total saponins 50g Carthamus yellow 50g
With Radix Ginseng total saponins, Carthamus yellow mix homogeneously, be dissolved in the phosphate buffer (0.1M) standby, a certain proportion of fabaceous lecithin, cholesterol are dissolved in the 18-amine. solution, add in the phosphate-buffered liquor of said medicine, the water-bath type Ultrasound Instrument is handled 8min, gets liposome turbid liquor, behind the frozen drying, cross 180 mesh sieves, aseptic subpackaged, promptly get the pro-liposome injectable powder.
Radix Ginseng total saponins among the above embodiment, Carthamus yellow can be with Radix Ginseng total saponins, Carthamus yellows commercially available or that make by the inventive method, no matter be alcohol extract, water extract, water extract-alcohol precipitation extract, semi-bionic extraction thing or supercritical extract etc., but, wherein the total saponin content of Radix Ginseng total saponins can guarantee the therapeutic effect of product like this greater than 50%.
Claims (12)
1, a kind of pharmaceutical composition for the treatment of cardiovascular and cerebrovascular disease is characterized in that: calculate according to percentage by weight, it is to be made by Radix Ginseng total saponins 1～99% and Flos Carthami flavochrome 99～1% and suitable adjuvant.
2, according to the pharmaceutical composition of the described treatment cardiovascular and cerebrovascular disease of claim 1, it is characterized in that: calculate according to percentage by weight, it is to be made by Radix Ginseng total saponins 95～50% and Flos Carthami flavochrome 5～50% and suitable adjuvant.
3, according to the pharmaceutical composition of claim 1 or 2 described treatment cardiovascular and cerebrovascular diseases, it is characterized in that: calculate according to percentage by weight, it is to be made by Radix Ginseng total saponins 90～50% and Flos Carthami flavochrome 10～50% and suitable adjuvant.
4, according to the pharmaceutical composition of any described treatment cardiovascular and cerebrovascular disease of claim 1～3, it is characterized in that: the Radix Ginseng total saponins in the described prescription can be the highly finished product of panaxynol extract, Radix Ginseng water extract, Radix Ginseng water extract-alcohol precipitation extract, Radix Ginseng semi-bionic extraction thing, Radix Ginseng supercritical extract or above each extract; Carthamus yellow can be the highly finished product of Flos Carthami alcohol extract, Flos Carthami water extract, Flos Carthami water extract-alcohol precipitation extract, Flos Carthami semi-bionic extraction thing, Flos Carthami supercritical extract or above each extract.
5, according to the pharmaceutical composition of any described treatment cardiovascular and cerebrovascular disease of claim 1～4, it is characterized in that: described composite preparation be directly used in the injection of drug administration by injection, directly for the venous transfusion of intravenous drip, need be used for the concentrated solution for injection of intravenous drip and injectable sterile powder and aseptic block and tablet, capsule, granule, drop pill, pill, pellet, soft capsule, oral liquid, oral cavity disintegration tablet or the dispersible tablet that makes with freeze-drying or spray drying method after the dilution.
6, according to the pharmaceutical composition of the described treatment cardiovascular and cerebrovascular disease of claim 5, it is characterized in that: described composite preparation can make on the basis that Radix Ginseng total saponins and Carthamus yellow is prepared into liposome or pro-liposome.
7, according to the pharmaceutical composition of any described treatment cardiovascular and cerebrovascular disease in the claim 1～6, it is characterized in that: contain saponin component and Flos Carthami flavochrome in the preparation, calculate by weight percentage, in the preparation saponin component, carthamus tinctorius yellow color content sum be not less than deduction adjuvant amount and water quantities in the preparation total solid 50%.
8, according to the pharmaceutical composition of the described treatment cardiovascular and cerebrovascular disease of claim 4, it is characterized in that: calculate according to percentage by weight, the content of saponin component is not less than 50% in the Radix Ginseng total saponins.
9, as the pharmaceutical composition of any described treatment cardiovascular and cerebrovascular disease in the claim 1～6, it is characterized in that:
A, described Carthamus yellow are preparations like this: get flos carthami, adding entry or alcoholic solution after the pulverizing extracts, merge extractive liquid,, filter, concentrate the Flos Carthami crude extract, adopt in ethanol precipitation, column chromatography, extraction, the flocculent precipitation one or more to unite on this basis to use carry out suitably refining, Carthamus yellow;
B, described Radix Ginseng total saponins effective site are preparations like this: get the ginseng crude drug, adding entry or alcoholic solution after the pulverizing extracts, merge extractive liquid,, filter, concentrate the Radix Ginseng crude extract, adopt in ethanol precipitation, column chromatography, extraction, the flocculent precipitation one or more to unite on this basis to use carry out suitably refining, Radix Ginseng total saponins effective site.
10, preparation of drug combination method according to any described treatment cardiovascular and cerebrovascular disease in the claim 1～6, it is characterized in that: the Injectable sterile block of described compositions prepares like this: get Radix Ginseng total saponins, Carthamus yellow, press medicine and added mannitol than 1: 2 with supplementary product consumption, add 1800ml water for injection, stirring makes dissolving, adjust pH to 5.5～6.5, add the injection water to 2000ml, mixing, the needle-use activated carbon of adding 0.5% boiled coarse filtration 30 minutes, reuse 0.45 μ m and 0.22 μ m microporous filter membrane filter, the filtrate packing, every bottle of 2.0ml, lyophilization, equilibration time when the balance solidification point of phase I is 0 ℃ is 2 hours, i.e. the time of shelf temperature and product temperature basically identical; The second stage solidification point is from 0 ℃ during to minimum eutectic temperature-18 ℃, and shelf temperature and product temperature equilibration time are 2 hours; Phase III continues to be cooled to-45 ℃, needs 2.5 hours approximately, keeps this temperature 2.5 hours, freeze the jail fully until product, promptly begin evacuation, enter drying program, evacuation under-45 ℃ of constant temperature slowly heats up 2～4 ℃/h, to the lowest total of the melting point temperature, the time is about 12 hours, after sublimation drying is finished, continuation is under the low pressure condition, and it is dry to remove residual moisture to heat up, and the time is about 8～10 hours, kept more than 35 ℃ dry 2 hours, gland, promptly.
11, according to the preparation of drug combination method of the described treatment cardiovascular and cerebrovascular disease of claim 6, it is characterized in that: the pro-liposome of described compositions prepares like this: get Radix Ginseng total saponins, Carthamus yellow, add the phosphate buffer dissolving, add in the fused solution of fabaceous lecithin, cholesterol and 18-amine. mixing, stir supersound process, freezing, the dry powder that obtains sieves, promptly.
12, as the application of the pharmaceutical composition of any described treatment cardiovascular and cerebrovascular disease in the claim 1～6, it is characterized in that: described compositions is mainly used in the application in disease medicaments such as preparation treatment ischemia apoplexy, angina pectoris, cardiac insufficiency, apoplexy sequela, hepatorenal syndrome, heart and lung diseases, diabetes and complication thereof.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510115952 CN1961904A (en) | 2005-11-11 | 2005-11-11 | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510115952 CN1961904A (en) | 2005-11-11 | 2005-11-11 | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1961904A true CN1961904A (en) | 2007-05-16 |
Family
ID=38081244
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510115952 Pending CN1961904A (en) | 2005-11-11 | 2005-11-11 | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1961904A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101474195B (en) * | 2008-12-24 | 2012-06-27 | 贵州信邦远东药业有限公司 | Medicament composition for treating cardiac and cerebral vascular disease |
-
2005
- 2005-11-11 CN CN 200510115952 patent/CN1961904A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101474195B (en) * | 2008-12-24 | 2012-06-27 | 贵州信邦远东药业有限公司 | Medicament composition for treating cardiac and cerebral vascular disease |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1981800A (en) | Chinese-medicinal preparation for treating cardiovascular diseases, its production and use | |
| CN1961904A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof | |
| CN1981801A (en) | Chinese-medicinal preparation for treating cardiovascular diseases, its production and use | |
| CN1961915A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof | |
| CN1961916A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof | |
| CN1961910A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof | |
| CN1961901A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof | |
| CN1961903A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof | |
| CN1961905A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof | |
| CN1961913A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof | |
| CN1961918A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof | |
| CN1961917A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof | |
| CN100998622A (en) | Traditional Chinese medicine preparations for treating cardiovascular and cerebrovascular diseases the preparation method and use thereof | |
| CN100998600A (en) | Traditional Chinese medicine preparation for treating cardiovascular or cerebrovascular diseases, preparing method and use thereof | |
| CN1965919A (en) | Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof | |
| CN1961900A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof | |
| CN100998641A (en) | Traditional Chinese medicine for treating cardiovascular and cerebrovascular disease, preparing method and use thereof | |
| CN100998643A (en) | Traditional Chinese medicine for treating cardiovascular and cerebrovascular disease, and preparing method and use thereof | |
| CN100998642A (en) | Traditional Chinese medicine for treating cardiovascular and cerebrovascular disease, preparing method and use thereof | |
| CN1961902A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof | |
| CN1961914A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof | |
| CN1961922A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof | |
| CN1961919A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof | |
| CN1961921A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof | |
| CN1961909A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |